Back
EN1

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Engage:Bdr Limited

πŸ‡¦πŸ‡Ί ASX

πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸƒ Esg

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual capital growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

1
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Engage:Bdr Limited

πŸ“ˆ Performance

Price History

-96.52%

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.01

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in EN1

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in EN1

1422 days
EN1 investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in EN1 also invest in...

ASIA

ASIA.AX was created on 2018-09-18 by BetaShares. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the BetaShares Asia Technology Tigers ETF is to provide an investment return that aims to track the performance of the Solactive Asia ex-Japan Technology & Internet Tigers Index (the Index), before taking into account fees and expenses.

πŸ“Š Share price

$7.28 AUD

NULL ASIA

Find Out More

1st Group Ltd. engages in the provision of online healthcare search and appointment booking services. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-06-09. The firm is engaged in the provision of healthcare, and corporate online search, and appointment booking services. The firm is engaged in building a virtual care technology company, Visionflex; an online pet service marketplace, PetYeti, and a corporate and government solutions platform, GoBookings.com. Visionflex's integrated clinical tools include an HD examination camera, real-time auscultation using digital stethoscopes, temperature sensors, blood-pressure cuff, blood-glucose monitors, ECG monitors, pulse oximeters, and weight scales. GoBookings provides a software-as-a-service (SaaS) booking platform for cloud-based enterprise level rules-based appointments and resource bookings. PetYeti provides online appointment booking for vet and pet services providers. The SaaS booking platform helps animal owners and vets to connect online across Australia and New Zealand.

πŸ“Š Share price

$0.01 AUD

88 Energy Ltd. is an oil and gas exploration company, which is engaged in the exploration and development of mineral properties. The company is headquartered in Subiaco, Western Australia and currently employs 10 full-time employees. The company went IPO on 2000-01-20. The firm is focused on oil exploration and appraisal activities across approximately 440,000 net acres in the Alaskan Central North Slope and NPR-A regions. The firm has a diversified portfolio of four prospective project areas: Project Icewine, Yukon Leases, Project Peregrine and the Umiat oil field. The Project Peregrine covers an area of approximately 195,973 acres. The Umiat Oil Field is located immediately adjacent to Project Peregrine. The Project Icewine is situated on the Central North Slope, Alaska and covers an area of approximately 193,000 acres. The Project Longhorn covers an area of approximately 1,300 net acres in West Andrews and Ector Countries in the Permian Basin.

πŸ“Š Share price

$0.01 AUD

AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. Its products include Neuvis, CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways. MicroMAX is an encapsulation technology for use in the field of animal therapeutics. Its subsidiaries include AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited.

πŸ“Š Share price

$0.04 AUD

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

πŸ“Š Share price

$57.36 AUD

NULL GLOBAL

NULL SMART BETA

Want more shares? Try these...

EN1AG

EMvision Medical Devices Ltd. engages in the development & commercialization of medical imaging technology. The company is headquartered in Brisbane, Queensland. The company went IPO on 2018-12-13. The firm is engaged in the research and development of medical imaging and diagnostic technology (the EMVision Technology), for the purpose of commercializing a portable medical device for stroke diagnosis and monitoring as well as other medical imaging needs. The firm is developing and commercializing medical imaging diagnostics for various disease states and medical emergencies. The Company’s product pipeline includes portable, non-invasive, neuroimaging devices. Its lead product in development includes a portable, non-ionizing brain scanner, capable of producing images of biological tissue to provide insights for clinicians. Its second-generation device is an ultra-light weight device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients regardless of location.

πŸ“Š Share price

$1.40 AUD